Form 8-K - Current report:
SEC Accession No. 0001144204-18-016720
Filing Date
2018-03-23
Accepted
2018-03-23 16:41:18
Documents
5
Period of Report
2018-03-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tv489360_8k.htm 8-K 20863
2 EXHIBIT 4.1 tv489360_ex4-1.htm EX-4.1 55381
3 EXHIBIT 10.1 tv489360_ex10-1.htm EX-10.1 117610
4 EXHIBIT 99.1 tv489360_ex99-1.htm EX-99.1 17180
5 GRAPHIC casi_logo.jpg GRAPHIC 5402
  Complete submission text file 0001144204-18-016720.txt   219921
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

EIN.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 18710612
SIC: 2836 Biological Products, (No Diagnostic Substances)